GO
Loading...

FDA

More

  • Big lobbying dollars flow in engineered food fight Tuesday, 29 Jul 2014 | 4:29 AM ET
    A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Analysts, who were surprised by the decision, said the issues cited by the FDA were "rather mild" and expected Zalviso to eventually receive approval. The FDA in its complete response letter sought more data to ensure proper use of the device but did not ask for additional human clinical trials.

  • July 28- Shares of AcelRx Pharmaceuticals Inc plunged nearly 28 percent in premarket trading, after the U.S. Food and Drug Administration rejected its pain drug device, Zalviso, late on Friday. AcelRx said it would resubmit its marketing application for Zalviso by the end of the year, pending further discussions with the FDA.

  • Reversing a lower court ruling, the 2nd U.S. Circuit Court of Appeals in New York said the FDA was empowered to reject two citizen challenges to its policy, which discourages but does not ban the use of penicillin and some tetracyclines in feed for chickens, cows and pigs, even if they are not sick.

  • Reversing a lower court ruling, the 2nd U.S. Circuit Court of Appeals in New York said the FDA was empowered to reject two citizen challenges to its policy, which discourages but does not ban the use of penicillin and some tetracyclines in feed for chickens, cows and pigs, even if they are not sick.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • U.S. FDA approves Gilead's blood cancer drug Zydelig Wednesday, 23 Jul 2014 | 12:05 PM ET

    July 23- The U.S. Food and Drug Administration has approved Gilead Inc's drug Zydelig to treat three types of blood cancer, the agency said on Wednesday. The FDA approved it for use in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • US drug laws cost consumers billions: Report Wednesday, 23 Jul 2014 | 11:51 AM ET

    U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.

  • Protections set up by the U.S. Food and Drug Administration called "risk evaluation and mitigation strategies", which can curb distribution of dangerous medicines, have been used to prevent generic drugmakers from getting the drugs in order to test their own versions, which is required to win FDA approval, the report from the Generic Pharmaceutical Association said.

  • July 23- Eagle Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its drug to treat an inherited life-threatening condition called malignant hyperthermia. Eagle Pharmaceuticals is also testing Ryanodex for use in exertional heatstroke.

  • U.S. District Court Judge Richard Leon ordered the FDA reconstitute the committee and barred the agency from using the panel's findings, which said removing menthol cigarettes from the market would benefit public health.

  • U.S. District Court Judge Richard Leon ordered the FDA reconstitute the committee and barred the agency from using the panel's findings, which said removing menthol cigarettes from the market would benefit public health.

  • NEW YORK, July 16- A proposal to overhaul nutrition labels on packaged foods sold in the United States does not go far enough to influence consumer choices and reduce obesity, a former U.S.

  • WASHINGTON, July 11- Last year the U.S. Food and Drug Administration recommended that millions of dollars in research grants be awarded to scientists serving on its tobacco advisory committee, even as it rejected several projects deemed by a National Institutes of Health panel to have greater scientific merit, according to confidential scores reviewed by Reuters.

  • July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail. The topical solution, Kerydin, is expected to be launched as early as the end of the quarter in the United States, the company said on Tuesday.

  • In preparatory documents posted on the agency's website on Tuesday, FDA reviewers said laparoscopic power morcellator devices, which are used to treat uterine fibroids, allow for less invasive surgeries, shorter recovery time and fewer wound site infections.

  • FDA approves Anacor Pharma's drug for nail infection Tuesday, 8 Jul 2014 | 8:49 AM ET

    July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the nail, sending the drug developer's shares up about 9 percent in premarket trade. Onychomycosis is a progressive, recurring fungal infection of the nail and nail bed and affects about 35 million people in the United States, Anacor said.

  • FDA approves Spectrum Pharma's blood cancer drug Thursday, 3 Jul 2014 | 11:19 AM ET

    July 3- Spectrum Pharmaceuticals Inc's drug for the treatment of an aggressive form of blood cancer was granted an accelerated approval by the U.S. Food and Drug Administration on Thursday. Beleodaq is the third drug to win approval for the condition since 2009, the other two being Spectrum's injection Folotyn and Celgene Corp's drug Istodax.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • July 2- St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California- based manufacturing plant have been resolved. The FDA last year had warned St.